Amag Pharmaceuticals Inc. missed the consensus mark on first-quarter sales of Makena (hydroxyprogesterone caproate) but nailed all the primary and secondary endpoints in the phase III trial testing the firm's approved Feraheme (ferumoxytol) compared to Injectafer (ferric carboxymaltose injection, Luitpold Pharmaceuticals Inc.) in adults with iron deficiency anemia (IDA).